Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.52 |
| ▸ | ITGAV | P06756 | 5/20 | 0.50 |
| ▸ | CTSG | P08311 | 2/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.50 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.50 |
| ▸ | KDM4A | O75164 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.48 |
| ▸ | NNMT | P40261 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 4/20 | 0.47 |
| ▸ | MC5R | P33032 | 4/20 | 0.47 |
| ▸ | MC3R | P41968 | 4/20 | 0.47 |
| ▸ | MC1R | Q01726 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24253294 | 0.94 | ITGB3 (0.56) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL23823921 | 0.94 | ITGB3 (0.56) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL20822613 | 0.94 | ITGB3 (0.56) | ITGB3ITGA2BITGAVITGB1ITGA5 | |
| SCHEMBL29393726 | 0.91 | ITGB3 (0.59) | CACNA1BITGB3ITGA2BITGAVCTSG | |
| SCHEMBL19412647 | 0.91 | ITGB3 (0.54) | CACNA1BITGB3ITGA2BITGAVCTSG | |
| SCHEMBL15160074 | 0.91 | ITGB3 (0.54) | CACNA1BITGB3ITGA2BITGAVCTSG | |
| SCHEMBL16135323 | 0.91 | ITGB3 (0.54) | CACNA1BITGB3ITGA2BITGAVCTSG | |
| SCHEMBL15308349 | 0.90 | ITGB3 (0.53) | CACNA1BITGB3ITGA2BITGAVCTSG | |
| SCHEMBL15160075 | 0.90 | ITGB3 (0.50) | CACNA1BITGB3ITGA2BITGAVCTSG | |
| SCHEMBL16301538 | 0.90 | ITGB3 (0.55) | CACNA1BITGB3ITGA2BITGAVCTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11357873-B2 | Chiral cyclen compounds and their uses | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20210283278-A1 | CHIRAL CYCLEN COMPOUNDS AND THEIR USES | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357873-B2 | Chiral cyclen compounds and their uses | DCTN3, DCTN1, CDK3 | CACNA1B 191/4885ITGB3 1516/4885ITGA2B 2553/4885 |
| US-20210283278-A1 | CHIRAL CYCLEN COMPOUNDS AND THEIR USES | DCTN3, DCTN1, CDK3 | CACNA1B 191/4885ITGB3 1516/4885ITGA2B 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.